お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
市場調査レポート
商品コード
948560

抗ウイルス療法の世界市場:タイプ、用途、作用機序別の機会分析と業界予測(2019年~2026年)

Anti-Viral Therapies Market by Type, Application, and Mechanism of Action: Global Opportunity Analysis and Industry Forecast, 2019-2026

出版日: | 発行: Allied Market Research | ページ情報: 英文 238 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
抗ウイルス療法の世界市場:タイプ、用途、作用機序別の機会分析と業界予測(2019年~2026年)
出版日: 2020年05月01日
発行: Allied Market Research
ページ情報: 英文 238 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の抗ウイルス療法市場は、2018年に383億1,650万米ドルとなりました。同市場は、2019年から2026年までの間に2.4%のCAGRで成長する見通しで、2026年には462億1,340万米ドルに達すると予測されています。同市場の主な成長要因は、ウイルス感染の発生率の増加が挙げられ、研究開発活動の増加や、パイプライン製品に加え、ワクチンや併用療法などの新たな先進薬剤の開発などが成長を後押しすると予測されています。また、アジア太平洋地域とラテンアメリカ・中東・アフリカの新興経済国における併用療法と開発・承認は、予測期間中の市場成長に多くの機会をもたらすと期待されています。ただし、治療にかかる高いコストと自然療法やホメオパシーなどの代替医療の需要の増加は、同市場の成長を抑制するおそれがあります。

当レポートは世界の抗ウイルス療法市場について調査しており、市場機会や影響、成長および抑制要因、用途・タイプ・作用機序・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資銘柄
    • 成功戦略
  • 市場力学
    • 成長要因
      • ウイルス感染による支出の急増
      • 抗ウイルス薬のより強力なパイプライン
    • 抑制要因
      • 治療費が高い
    • 市場機会
      • 併用療法の製品承認数の増加

第4章 市場分析:用途別

  • 概観
    • 市場規模と予測
  • HIV
  • 肝炎
  • ヘルペスウイルス
  • インフルエンザ
  • その他

第5章 市場分析:タイプ別

  • 概観
    • 市場規模と予測
  • ジェネリック医薬品
  • ブランド薬

第6章 市場分析:作用機序別

  • 概観
    • 市場規模と予測
  • ヌクレオチドポリメラーゼ阻害剤
  • 逆転写酵素阻害剤
  • プロテアーゼ阻害剤
  • その他

第7章 市場分析:地域別

  • 概観
    • 市場規模と予測
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ・中東・アフリカ

第8章 企業プロファイル

  • Abbott Laboratories
  • AbbVie Inc.
  • Bristol Myers Squibb Company
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • GILEAD SCIENCES, INC.
  • GlaxoSmithKline Plc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
図表

LIST OF TABLES

  • TABLE 01.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY APPLICATION, 2018-2026 ($MILLION)
  • TABLE 02.HIV ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 03.HEPATITIS ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 04.HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 05.INFLUENZA ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 06.OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY REGION, 2018-2026 ($MILLION)
  • TABLE 07.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY TYPE, 2018-2026 ($MILLION)
  • TABLE 08.ANTI-VIRAL THERAPIES MARKET FOR GENERIC DRUGS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 09.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 10.GLOBAL ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION, 2018-2026 ($MILLION)
  • TABLE 11.ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR, BY REGION, 2018-2026 ($MILLION)
  • TABLE 12.ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 13.ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 14.ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY REGION, 2018-2026 ($MILLION)
  • TABLE 15.GLOBAL ANTI-VIRAL THERAPIES MARKET BY REGION, 2018-2026, ($MILLION)
  • TABLE 16.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 17.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 18.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 19.NORTH AMERICA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 20.U.S. ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 21.U.S. ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 22.U.S. ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 23.CANADA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 24.CANADA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 25.CANADA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 26.MEXICO ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 27.MEXICO ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 28.MEXICO ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 29.EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 30.EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 31.EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 32.EUROPE ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 33.GERMANY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 34.GERMANY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 35.GERMANY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 36.FRANCE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 37.FRANCE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 38.FRANCE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 39.UK ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 40.UK ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 41.UK ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 42.ITALY ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 43.ITALY ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 44.ITALY ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 45.SPAIN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 46.SPAIN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 47.SPAIN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 48.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 49.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 50.REST OF EUROPE ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 51.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 52.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 53.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 54.ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 55.JAPAN ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 56.JAPAN ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 57.JAPAN ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 58.CHINA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 59.CHINA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 60.CHINA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 61.INDIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 62.INDIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 63.INDIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 64.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 65.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 66.AUSTRALIA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 67.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 68.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 69.SOUTH KOREA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 70.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 71.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 72.REST OF ASIA-PACIFIC ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 73.LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 74.LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 75.LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 76.LAMEA ANTI-VIRAL THERAPIES MARKET BY COUNTRY, 2018-2026, ($MILLION)
  • TABLE 77.BRAZIL ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 78.BRAZIL ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 79.BRAZIL ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 80.SAUDI ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 81.SAUDI ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 82.SAUDI ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 83.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 84.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 85.SOUTH AFRICA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 86.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY TYPE, 2018-2026, ($MILLION)
  • TABLE 87.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY MECHANISM OF ACTION, 2018-2026, ($MILLION)
  • TABLE 88.REST OF LAMEA ANTI-VIRAL THERAPIES MARKET BY APPLICATION, 2018-2026, ($MILLION)
  • TABLE 89.ABBOTT: COMPANY SNAPSHOT
  • TABLE 90.ABBOTT: OPERATING SEGMENTS
  • TABLE 91.ABBOTT: PRODUCT PORTFOLIO
  • TABLE 92.ABBVIE: COMPANY SNAPSHOT
  • TABLE 93.ABBVIE: OPERATING SEGMENTS
  • TABLE 94.BMS: COMPANY SNAPSHOT
  • TABLE 95.BMS: OPERATING SEGMENTS
  • TABLE 96.BMS: PRODUCT PORTFOLIO
  • TABLE 97.ROCHE: COMPANY SNAPSHOT
  • TABLE 98.ROCHE: OPERATING SEGMENTS
  • TABLE 99.ROCHE: PRODUCT PORTFOLIO
  • TABLE 100.J&J: COMPANY SNAPSHOT
  • TABLE 101.J&J: OPERATING SEGMENTS
  • TABLE 102.MERCK: COMPANY SNAPSHOT
  • TABLE 103.MERCK: OPERATING SEGMENTS
  • TABLE 104.GILEAD: COMPANY SNAPSHOT
  • TABLE 105.GILEAD: OPERATING SEGMENTS
  • TABLE 106.GILEAD: PRODUCT PORTFOLIO
  • TABLE 107.GSK.: COMPANY SNAPSHOT
  • TABLE 108.GSK: OPERATING SEGMENTS
  • TABLE 109.GSK: PRODUCT PORTFOLIO
  • TABLE 110.ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 111.ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 112.ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 113.AUROBINDO: COMPANY SNAPSHOT
  • TABLE 114.AUROBINDO: OPERATING SEGMENTS
  • TABLE 115.AUROBINDO: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01.ANTI-VIRAL THERAPIES MARKET SEGMENTATION
  • FIGURE 01.TOP INVESTMENT POCKETS
  • FIGURE 02.TOP WINNING STRATEGIES, BY YEAR, 2016-2019*
  • FIGURE 03.TOP WINNING STRATEGIES, BY DEVELOPMENT, 2016-2019* (%)
  • FIGURE 04.TOP WINNING STRATEGIES, BY COMPANY, 2016-2019*
  • FIGURE 05.TOP IMPACTING FACTORS
  • FIGURE 06.COMPARATIVE ANALYSIS OF HIV ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 07.COMPARATIVE ANALYSIS OF HEPATITIS ANTI VIRAL THERAPIES MARKE BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 08.COMPARATIVE ANALYSIS OF HERPES VIRUS ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 09.COMPARATIVE ANALYSIS OF INFLUENZA ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 10.COMPARATIVE ANALYSIS OF OTHER APPLICATIONS ANTI VIRAL THERAPIES MARKET BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 11.ANTI-VIRAL THERAPIES FOR GENERIC DRUGS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 12.ANTI-VIRAL THERAPIES MARKET FOR BRANDED DRUGS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 13.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET, FOR NUCLEOTIDE POLYMERASE INHIBITOR BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 14.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 15.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR PROTEASE INHIBITORS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 16.COMPARATIVE ANALYSIS OF ANTI-VIRAL THERAPIES MARKET FOR OTHERS, BY COUNTRY, 2018 & 2026 (%)
  • FIGURE 17.ABBOTT: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 18.ABBOTT: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 19.ABBOTT: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 20.ABBVIE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 21.ABBVIE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 22.ABBVIE: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 23.BMS: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 24.BMS: REVENUE SHARE BY SEGMENT, 2018(%)
  • FIGURE 25.BMS: REVENUE SHARE BY REGION, 2018(%)
  • FIGURE 26.ROCHE: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 27.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 28.ROCHE: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 29.J&J: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 30.J&J: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 31.J&J: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 32.MERCK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 33.MERCK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 34.GILEAD: REVENUE, 2016-2018($MILLION)
  • FIGURE 35.GILEAD: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 36.GSK: REVENUE, 2016-2018($MILLION)
  • FIGURE 37.GSK: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 38.GSK: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 39.ASTRAZENECA: NET SALES, 2016-2018 ($THOUSAND)
  • FIGURE 40.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 41.ASTRAZENECA: REVENUE SHARE BY REGION, 2018 (%)
  • FIGURE 42.AUROBINDO: NET SALES, 2016-2018 ($MILLION)
  • FIGURE 43.AUROBINDO: REVENUE SHARE BY SEGMENT, 2018 (%)
  • FIGURE 44.AUROBINDO: REVENUE SHARE BY REGION, 2018 (%)
目次
Product Code: A06278

Title:
Anti-Viral Therapies Market by Type (Generic Drugs and Branded Drugs), Application (HIV, Hepatitis, Herpes Virus, Influenza, and Other Applications), and Mechanism of Action (Nucleotide Polymerase Inhibitor, Reverse Transcriptase Inhibitors, Protease Inhibitors, and Others): Global Opportunity Analysis and Industry Forecast, 2019-2026.

The global anti-viral therapies market was valued at $38,316.5 million in 2018, and is projected to reach $46,213.4 million by 2026 registering a CAGR of 2.4% from 2019 to 2026. Antiviral drugs belong to the class of medicines, which are used for treating viral infections, such as HIV, herpes, hepatitis, and influenza. These drugs are generally administered in the form of vaccines. In addition, most of these drugs are used for specific viral infections, while a few (broad-spectrum antiviral drugs) are effective against a wide range of viruses.

The global antiviral therapies market is majorly driven by increase in the incidence rate of viral infections. In addition, rise in R&D activities and development of newer & advanced formulations, such as vaccines and combination therapy along with pipeline products, are expected to fuel the market growth. However, high cost involved in the treatment and rise in demand for alternative medicines such as naturopathy and homeopathy are likely to restrain the market growth. On the contrary, development and approvals of combination therapies and growth opportunities in the emerging economies of Asia-Pacific and LAMEA regions are anticipated to provide numerous opportunities for the market growth during the forecast period.

The global antiviral therapies market is segmented on the basis of application, type, mechanism of action, and region. Based on application, the market is categorized into HIV, hepatitis, herpes, influenza, and other viral diseases. On the basis of type, it is classified into generic drugs and branded drugs. By mechanism of action, it is divided into nucleotide polymerase inhibitors, reverse transcriptase inhibitors, protease inhibitors, and others. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

KEY BENEFITS FOR STAKEHOLDERS

This report provides a detailed quantitative analysis of the current market trends and future estimations from 2019 to 2026, which assists to identify the prevailing market opportunities.

An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.

A comprehensive analysis of the factors that drive and restrain the growth of the global clinical nutrition market is provided.

An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.

KEY MARKET SEGMENTS

By Application

  • HIV
  • Hepatitis
  • Herpes Virus
  • Influenza
  • Other Applications

By Type

  • Generic Drugs
  • Branded Drugs

By Mechanism of Action

  • Nucleotide Polymerase Inhibitor
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Others

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • Spain
  • Italy
  • UK
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA
  • KEY MARKET PLAYERS
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, GlaxoSmithKline
  • Bristol-Myers-Squibb
  • Abbott Laboratories
  • AstraZeneca plc
  • AbbVie Inc.
  • Aurobindo Pharma Limited
  • Johnson & Johnson
  • Merck & Co., Inc

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key benefits for stakeholders
  • 1.3.Key market segments
  • 1.4.Research methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
    • 3.2.2.Top winning strategies
  • 3.3.Market dynamics
    • 3.3.1.Drivers
      • 3.3.1.1.Surge in global burden of viral infection
      • 3.3.1.2.Stronger pipeline of anti-viral drugs
    • 3.3.2.Restraints
      • 3.3.2.1.Higher cost of treatment
    • 3.3.3.Opportunities
      • 3.3.3.1.Increase in number of product approvals for combination therapy

CHAPTER 4:ANTI-VIRAL THERAPIES MARKET, BY APPLICATION

  • 4.1.Overview
    • 4.1.1.Market size and forecast
  • 4.2.HIV
    • 4.2.1.Key market trends, growth factors, and opportunities
    • 4.2.2.Market size and forecast, by region
    • 4.2.3.Market analysis, by country
  • 4.3.Hepatitis
    • 4.3.1.Key market trends, growth factors, and opportunities
    • 4.3.2.Market size and forecast, by region
    • 4.3.3.Market analysis, by country
  • 4.4.Herpes virus
    • 4.4.1.Key market trends, growth factors, and opportunities
    • 4.4.2.Market size and forecast, by region
    • 4.4.3.Market analysis, by country
  • 4.5.Influenza
    • 4.5.1.Key market trends, growth factors, and opportunities
    • 4.5.2.Market size and forecast, by region
    • 4.5.3.Market analysis, by country
  • 4.6.Other Applications
    • 4.6.1.Key market trends, growth factors, and opportunities
    • 4.6.2.Market size and forecast, by region
    • 4.6.3.Market analysis, by country

CHAPTER 5:ANTI-VIRAL THERAPIES MARKET, BY TYPE

  • 5.1.Overview
    • 5.1.1.Market size and forecast
  • 5.2.Generic drugs
    • 5.2.1.Market size and forecast, by region
    • 5.2.2.Market analysis, by country
  • 5.3.Branded drugs
    • 5.3.1.Market size and forecast, by region
    • 5.3.2.Market analysis, by country

CHAPTER 6:ANTI-VIRAL THERAPIES MARKET, BY MECHANISM OF ACTION

  • 6.1.Overview
    • 6.1.1.Market size and forecast
  • 6.2.Nucleotide polymerase inhibitor
    • 6.2.1.Market size and forecast, by region
    • 6.2.2.Market analysis, by country
  • 6.3.Reverse transcriptase inhibitors
    • 6.3.1.Market size and forecast, by region
    • 6.3.2.Market analysis, by country
  • 6.4.Protease inhibitors
    • 6.4.1.Market size and forecast, by region
    • 6.4.2.Market analysis, by country
  • 6.5.Others
    • 6.5.1.Market size and forecast, by region
    • 6.5.2.Market analysis, by country

CHAPTER 7:GLOBAL ANTI-VIRAL THERAPIES MARKET, BY REGION

  • 7.1.Overview
    • 7.1.1.Market size and forecast
  • 7.2.North America
    • 7.2.1.Key market trends and opportunities
    • 7.2.2.Market size and forecast, by type
    • 7.2.3.Market size and forecast, by mechanism of action
    • 7.2.4.Market size and forecast, by application
    • 7.2.5.Market size and forecast, by country
      • 7.2.5.1.U.S. market size and forecast, by type
      • 7.2.5.2.U.S. Market size and forecast, by mechanism of action
      • 7.2.5.3.U.S. market size and forecast, by application
      • 7.2.5.4.Canada market size and forecast, by type
      • 7.2.5.5.Canada Market size and forecast, by mechanism of action
      • 7.2.5.6.Canada market size and forecast, by application
      • 7.2.5.7.Mexico market size and forecast, by type
      • 7.2.5.8.Mexico Market size and forecast, by mechanism of action
      • 7.2.5.9.Mexico market size and forecast, by application
  • 7.3.Europe
    • 7.3.1.Key market trends and opportunities
    • 7.3.2.Market size and forecast, by type
    • 7.3.3.Market size and forecast, by mechanism of action
    • 7.3.4.Market size and forecast, by application
    • 7.3.5.Market size and forecast, by country
      • 7.3.5.1.Germany market size and forecast, by type
      • 7.3.5.2.Germany Market size and forecast, by mechanism of action
      • 7.3.5.3.Germany market size and forecast, by application
      • 7.3.5.4.France market size and forecast, by type
      • 7.3.5.5.France Market size and forecast, by mechanism of action
      • 7.3.5.6.France market size and forecast, by application
      • 7.3.5.7.UK market size and forecast, by type
      • 7.3.5.8.UK Market size and forecast, by mechanism of action
      • 7.3.5.9.UK market size and forecast, by application
      • 7.3.5.10.Italy market size and forecast, by type
      • 7.3.5.11.Italy Market size and forecast, by mechanism of action
      • 7.3.5.12.Italy market size and forecast, by application
      • 7.3.5.13.Spain market size and forecast, by type
      • 7.3.5.14.Spain Market size and forecast, by mechanism of action
      • 7.3.5.15.Spain market size and forecast, by application
      • 7.3.5.16.Rest of Europe market size and forecast, by type
      • 7.3.5.17.Rest of Europe Market size and forecast, by mechanism of action
      • 7.3.5.18.Rest of Europe market size and forecast, by application
  • 7.4.Asia-Pacific
    • 7.4.1.Key market trends and opportunities
    • 7.4.2.Market size and forecast, by type
    • 7.4.3.Market size and forecast, by mechanism of action
    • 7.4.4.Market size and forecast, by application
    • 7.4.5.Market size and forecast, by country
      • 7.4.5.1.Japan market size and forecast, by type
      • 7.4.5.2.Japan Market size and forecast, by mechanism of action
      • 7.4.5.3.Japan market size and forecast, by application
      • 7.4.5.4.China market size and forecast, by type
      • 7.4.5.5.China Market size and forecast, by mechanism of action
      • 7.4.5.6.China market size and forecast, by application
      • 7.4.5.7.India market size and forecast, by type
      • 7.4.5.8.India Market size and forecast, by mechanism of action
      • 7.4.5.9.India market size and forecast, by application
      • 7.4.5.10.Australia market size and forecast, by type
      • 7.4.5.11.Australia Market size and forecast, by mechanism of action
      • 7.4.5.12.Australia market size and forecast, by application
      • 7.4.5.13.South Korea market size and forecast, by type
      • 7.4.5.14.South Korea Market size and forecast, by mechanism of action
      • 7.4.5.15.South Korea market size and forecast, by application
      • 7.4.5.16.Rest of Asia-Pacific market size and forecast, by type
      • 7.4.5.17.Rest of Asia-Pacific Market size and forecast, by mechanism of action
      • 7.4.5.18.Rest of Asia-Pacific market size and forecast, by application
  • 7.5.LAMEA
    • 7.5.1.Key market trends and opportunities
    • 7.5.2.Market size and forecast, by type
    • 7.5.3.Market size and forecast, by mechanism of action
    • 7.5.4.Market size and forecast, by application
    • 7.5.5.Market size and forecast, by country
      • 7.5.5.1.Brazil market size and forecast, by type
      • 7.5.5.2.Brazil Market size and forecast, by mechanism of action
      • 7.5.5.3.Brazil market size and forecast, by application
      • 7.5.5.4.Saudi market size and forecast, by type
      • 7.5.5.5.Saudi Market size and forecast, by mechanism of action
      • 7.5.5.6.Saudi market size and forecast, by application
      • 7.5.5.7.South Africa market size and forecast, by type
      • 7.5.5.8.South Africa Market size and forecast, by mechanism of action
      • 7.5.5.9.South Africa market size and forecast, by application
      • 7.5.5.10.Rest of LAMEA market size and forecast, by type
      • 7.5.5.11.Rest of LAMEA Market size and forecast, by mechanism of action
      • 7.5.5.12.Rest of LAMEA market size and forecast, by application

CHAPTER 8:COMPANY PROFILES

  • 8.1.Abbott Laboratories
    • 8.1.1.Company overview
    • 8.1.2.Company snapshot
    • 8.1.3.Operating business segments
    • 8.1.4.Product portfolio
    • 8.1.5.Business performance
  • 8.2.AbbVie Inc.
    • 8.2.1.Company overview
    • 8.2.2.Company snapshot
    • 8.2.3.Operating business segments
    • 8.2.4.Business performance
    • 8.2.5.Key strategic moves and developments
  • 8.3.Bristol Myers Squibb Company
    • 8.3.1.Company overview
    • 8.3.2.Company snapshot
    • 8.3.3.Operating business segments
    • 8.3.4.Product portfolio
    • 8.3.5.Business performance
  • 8.4.F. Hoffmann-La Roche Ltd.
    • 8.4.1.Company overview
    • 8.4.2.Company snapshot
    • 8.4.3.Operating business segments
    • 8.4.4.Product portfolio
    • 8.4.5.Business performance
    • 8.4.6.Key strategic moves and developments
  • 8.5.Johnson & Johnson
    • 8.5.1.Company overview
    • 8.5.2.Company snapshot
    • 8.5.3.Operating business segments
    • 8.5.4.Business performance
  • 8.6.Merck & Co., Inc.
    • 8.6.1.Company overview
    • 8.6.2.Company snapshot
    • 8.6.3.Operating business segments
    • 8.6.4.Business performance
    • 8.6.5.Key strategic moves and developments
  • 8.7.GILEAD SCIENCES, INC.
    • 8.7.1.Company overview
    • 8.7.2.Company snapshot
    • 8.7.3.Operating business segments
    • 8.7.4.Product portfolio
    • 8.7.5.Business performance
    • 8.7.6.Key strategic moves and developments
  • 8.8.GlaxoSmithKline Plc.
    • 8.8.1.Company overview
    • 8.8.2.Company snapshot
    • 8.8.3.Operating business segments
    • 8.8.4.Product portfolio
    • 8.8.5.Business performance
    • 8.8.6.Key strategic moves and developments
  • 8.9.AstraZeneca PLC
    • 8.9.1.Company overview
    • 8.9.2.Company snapshot
    • 8.9.3.Operating business segments
    • 8.9.4.Product portfolio
    • 8.9.5.Business performance
    • 8.9.6.Key strategic moves and developments
  • 8.10.Aurobindo Pharma Limited
    • 8.10.1.Company overview
    • 8.10.2.Company snapshot
    • 8.10.3.Operating business segments
    • 8.10.4.Product portfolio
    • 8.10.5.Business performance
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.